Medigene AG: New research collaborations and additional grant for immunotherapy TABs
Preclinical in vivo data about the treatment of autoimmune diseases and T cell leukemia with monoclonal antibodies generated during the granted period will be of great value for further clinical development of this immunotherapy platform. Overall, the collaboration with both research institutions offers Medigene extended scientific synergies regarding technology transfer, infrastructure and exchange of knowledge.
Additionally, Trianta will receive increased public funding for its immunotherapy platform TABs. The grant which has already been awarded by the Federal Ministry of Education and Research, (Bundesministerium für Bildung und Forschung = BMBF) within the scope of the "m4 - Personalized Medicine and Targeted Therapies: a new Dimension of Drug Development" Munich Leading-Edge Cluster initiative in beginning of June, now has been increased. The sponsored project intends to provide evidence of the elimination of pathogenic T cells in T-cell leukemia and autoimmune diseases, applying in-vivo and in-vitro methods with T-cell receptor-specific monoclonal antibodies. The project is financed by Medigene (60%) as well as the BMBF grant (40%).
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous